Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Matuzumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Matuzumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Merestinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Merestinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Mezigdomide |
IMiD (Cereblon Modulator) | Hematologic (Multiple Myeloma) | ||
|
Molecule
Mezigdomide
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
||||
Midostaurin |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Midostaurin
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Mifamurtide |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Mifamurtide
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Milademetan |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Milademetan
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
Mirdametinib |
MEK1/2 Inhibitor | Solid Tumour | ||
|
Molecule
Mirdametinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MEK1/2 Inhibitor |
||||
Mirvetuximab Soravtansine |
ADC | Solid Tumour | ||
|
Molecule
Mirvetuximab Soravtansine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
MK-2206 (AKT Inhibitor) |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
MK-2206 (AKT Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Mocetinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Mocetinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Momelotinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Momelotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Mosunetuzumab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Mosunetuzumab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
MatuzumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
MerestinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
MezigdomideImmunomodulatory Agent |
|
|
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
|
MidostaurinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
MifamurtideTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
MilademetanTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|
MirdametinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MEK1/2 Inhibitor |
|
Mirvetuximab SoravtansineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
MK-2206 (AKT Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
MocetinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
MomelotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
MosunetuzumabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|